Bernard Fox: 100 New Cancer Immunotherapy drug approvals in the next decade

Bernard Fox, Co-Founder and CEO of UbiVac, shared on LinkedIn:

“100 New Cancer Immunotherapy drug approvals in the next decade! Thrilled to be in Lake Geneva, WI, for the Society for Immunotherapy of Cancer (SITC) Strategic Retreeat. One goal is to identify hurdles needed to be overcome to obtain approval for 100 new immunotherapy-oncology drugs by the FDA in the next decade. It is my opinion that by monitoring serial biopsies of patients on phase I clinical trials that we will unravel the roadblocks that keep patients from having their cancers regress.

Dr. Rom Leidner ‘reported at AACR2024 insights from a trial with Incyte and UbiVac. That trial saw a doubling to >3x increase response rate (RR) Over std therapy. The monitoring suggested a strategy that might further increase RR. I believe a next generation of trials based on solid evidence from this type of monitoring will yield the breakthroughs patients are waiting for! N.B. Developing Combo I-O agents is not for sissies!”

Video attached to the post.
Source: Bernard Fox/LinkedIn